Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2011-11-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2011.1703PMID 22088980
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.

  2011cited by this paper
• High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

  2011cited by this paper
• Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.

  2011cited by this paper
• Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects

  2011cited by this paper
• High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

  2011cited by this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.

  2011cited by this paper
• Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial

  2011cited by this paper
• Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.

  2011cited by this paper
• Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.

  2010cited by this paper
• Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

  2010cited by this paper
• Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.

  2010cited by this paper
• Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.

  2010cited by this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes

  2009cited by this paper
• Can we override clopidogrel resistance?

  2009cited by this paper
• Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.

  2009cited by this paper
• Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.

  2009cited by this paper
• Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

  2009cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

  2008cited by this paper
• Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

  2008cited by this paper
• The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

  2008cited by this paper
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

  2007cited by this paper
• Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

  2005cited by this paper
• Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.

  2005cited by this paper
• Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

  2002cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION

  2001cited by this paper

• Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.

  2026cites this paper
• Drug response testing for elective carotid artery stenting: Prevalence of non-response to aspirin and clopidogrel and influence on post-interventional occurrence of cerebral ischemia.

  2025cites this paper
• An integrative framework for precision medication in hypertension: Applying a dialectical perspective to traditional Chinese and Western medicine

  2025cites this paper
• Platelet aggregation rate serves as a significant predictive indicator for thromboembolic events in the context of stent-assisted embolization for unruptured arterial aneurysms

  2025cites this paper
• Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.

  2025cites this paper
• Pharmaceutical and clinical implications of proton pump inhibitors with dual antiplatelet therapies: a systematic review

  2025cites this paper
• Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing

  2025cites this paper
• Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative.

  2025cites this paper
• Global trends and research hotspots in acupuncture treatment for cardiovascular diseases over the past decade: a bibliometric study

  2025cites this paper
• Evaluation of pharmacogenomic testing to identify cytochrome P450 and SLCO1B1 enzymes and adverse drug events: A non-experimental observational research

  2025cites this paper
• The efficacy and safety of aspirin-ticagrelor vs. aspirin-clopidogrel in ischemic stroke patients with cerebral artery stenting.

  2024cites this paper
• Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications.

  2024cites this paper
• International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention: 2024 Update.

  2024cites this paper
• CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association

  2024cites this paper
• Effect of loss-of-function CYP2C19 variants on clinical outcomes in coronary artery disease patients treated with clopidogrel: A systematic meta-analysis approach.

  2024cites this paper
• Outcomes of Ticagrelor Versus High-dose Clopidogrel in CYP2C19 Intermediate Metabolizer Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes

  2024cites this paper
• Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis.

  2024cites this paper
• Antiplatelet Therapy and Platelet Activity Testing for Neurointerventional Procedures

  2024cites this paper
• Investigation of smoking on the antiplatelet response to clopidogrel: Unravelling the smoker's paradox.

  2024cites this paper
• Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.

  2024cites this paper
• Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.

  2024cites this paper
• Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel

  2023cites this paper
• Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

  2023cites this paper
• Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review

  2023cites this paper
• Pharmacogenetics of P2Y12 receptor inhibitors

  2023cites this paper
• Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk

  2023cites this paper
• The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study

  2023cites this paper
• Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

  2023cites this paper
• Cardiovascular precision medicine – A pharmacogenomic perspective

  2023cites this paper
• Platelets and the Atherosclerotic Process: An Overview of New Markers of Platelet Activation and Reactivity, and Their Implications in Primary and Secondary Prevention

  2023cites this paper
• Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease

  2023cites this paper
• CYP2C19 and effect of clopidogrel for secondary prevention of major ischemic events: systematic review and meta-analysis

  2023cites this paper
• Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin

  2023cites this paper
• Integrative omics – An arsenal for drug discovery

  2022cites this paper
• Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation

  2022cites this paper
• Clinical pharmacogenetics

  2022cites this paper
• Personalizing treatments for patients based on cardiovascular phenotyping

  2022cites this paper
• High‐Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta‐Analysis of Randomized Trials

  2022cites this paper
• Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives

  2022cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

  2022cites this paper
• The effect of ticagrelor and clopidogrel on angiographic parameters according to diabetic status in patients with ST elevation myocardial infarction

  2022cites this paper
• Pharmacogenetics of Antiplatelet Therapy.

  2022cites this paper
• Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model

  2022cites this paper
• Impact of CYP2C19 gene polymorphisms on clinical outcomes in patients with myocardial infarction during 12-month follow-up

  2022cites this paper
• PGPM_A_324612 1575..1582

  2021cites this paper
• MicroRNAs as Novel Biomarkers for P2Y12 – Inhibitors Resistance Prediction

  2021cites this paper
• Impact of Automated Best Practice Advisories on Provider Response to CYP2C19 Genotyping Results for Patients on Clopidogrel

  2021cites this paper
• Leveraging innovative technology to generate drug response phenotypes for the advancement of biomarker‐driven precision dosing

  2021cites this paper
• Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment

  2021cites this paper
• Revascularization of acute stent thrombosis after carotid artery stenting in a CYP2C19*2 heterozygote patient

  2021cites this paper
• Pharmacogenetics to guide cardiovascular drug therapy

  2021cites this paper
• Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India

  2021cites this paper
• Use of Thromboelastography Platelet Mapping for Assessment of Individual Platelet Response Secondary to Oral Antiplatelet Therapy after Percutaneous Coronary Intervention: An Attempt to Start Personalized Antiplatelet Therapy in India

  2021cites this paper
• Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis.

  2021cites this paper
• Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism

  2021cites this paper
• Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race‐Conscious Medicine

  2021cites this paper
• Intensified P2Y12 inhibition for high-on treatment platelet reactivity

  2020cites this paper
• CPAA_A_242675 35..41

  2020cites this paper
• Prospective CYP2C19 Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention

  2020cites this paper
• Contribution of exome sequencing to the identification of genes involved in the response to clopidogrel in cardiovascular patients

  2020cites this paper
• The application of big data to cardiovascular disease: paths to precision medicine.

  2020cites this paper
• Genetic background of coronary artery disease: clinical implications and perspectives

  2020cites this paper
• Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada

  2020cites this paper
• Antiplatelet effect of ticagrelor with aspirin in acute minor stroke and transient ischemic attack stratified by CYP2C19 metabolizer status: subgroup analysis of the PRINCE trial

  2020cites this paper
• Pharmacogenetic testing: 5 Questions

  2020cites this paper
• Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke

  2020influential citation
• Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.

  2020cites this paper
• Prevalence and types of genetic polymorphisms of CYP2C19 and their effects on platelet aggregation inhibition by clopidogrel.

  2020cites this paper
• Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients

  2020cites this paper
• Correlation between CYP2C19 gene polymorphism and clinical efficacy of clopidogrel in patients with coronary artery heart disease

  2020cites this paper
• Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy

  2020cites this paper
• CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls

  2020cites this paper
• Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention

  2020cites this paper
• Effectiveness and safety of high dose clopidogrel plus aspirin in ischemic stroke patients with the single CYP2C19 loss-of-function allele: a randomized trial

  2020cites this paper
• Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients

  2020cites this paper
• Effectiveness of personalized antiplatelet therapy in patients undergoing coronary stenting: meta-analysis

  2019cites this paper
• Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention

  2019cites this paper
• Revascularization of Acute Stent Thrombosis after Carotid Artery Stenting in Clopidogrel Resistance Patient

  2019cites this paper
• Platelet Function Testing in Clinical Research Trials

  2019cites this paper
• Nakolik splňujeme v praxi standardy antiagregační léčby v sekundární prevenci infarktu myokardu

  2019cites this paper
• Pharmacogenomics

  2019cites this paper
• One Step Closer to Precision Medicine Strategies Based on Genetic Information: ABCB1 Polymorphisms in the CHANCE Trial.

  2019cites this paper
• Revascularization of Acute Stent Thrombosis after  Carotid Artery Stenting in a Clopidogrel Resistance Patient

  2019cites this paper
• The Efficacy of P2Y12 Reactive Unit to Predict the Periprocedural Thromboembolic and Hemorrhagic Complications According to Clopidogrel Responsiveness and Safety of Modification of Dual Antiplatelet Therapy : A Meta-Analysis

  2019cites this paper
• Clopidogrel Pharmacogenetics - Why the Wait?

  2019cites this paper
• The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review

  2019cites this paper
• Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases

  2019cites this paper
• Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention

  2019cites this paper
• (In what extent we reached the standards of antiplatelet therapy in secondary prevention of myocardial infarction)

  2019cites this paper
• Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy

  2019cites this paper
• Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

  2019cites this paper
• Cytochrome p450 and VKORC1 Genotyping for Treatment Selection and Dosing

  2019cites this paper
• Aspirin and Clopidogrel Resistance in Indian Patients with Ischemic Stroke and its Associations with Gene Polymorphisms: A Pilot Study

  2019cites this paper
• Challenges and Future in Precision Cardiovascular Medicine

  2019cites this paper
• 2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.

  2019influential citation
• Influence of smoking on CYP2C19 genetic variants and clopidogrel efficacy in patients with minor stroke or transient ischaemic attack

  2019cites this paper
• Pharmacogenetics in Cardiovascular Diseases

  2019cites this paper
• Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study

  2019cites this paper
• [The design of the software system for the interpretation and guidance of drug locus related to drug treatment].

  2019cites this paper
• Cytochrome p450 and VKORC1 Genotyping for Treatment Selection and Dosing

  2018cites this paper